Oral Drug LW-1017 Clears Alzheimer's and Parkinson's Proteins in Aged Mice
Lysoway's LW-1017 reactivates the brain's lysosomal cleanup system, reducing toxic protein buildup in aged mouse models of both diseases.
Summary
A small-molecule drug called LW-1017, developed by Lysoway Therapeutics, activates a protein on lysosomes — the cell's recycling centers — to restore the brain's natural cleanup process. In aged mouse models, the oral drug reduced the toxic protein clumps associated with both Alzheimer's and Parkinson's disease, protected neurons, and improved memory and movement. The drug works by opening a calcium channel called TRPML1, triggering genes that ramp up cellular waste removal. It also showed strong brain penetration at low doses, which the company says improves both safety and efficacy. The findings are published in Scientific Reports. Human trials are in early Phase I, so clinical translation remains uncertain, but the dual-disease approach and lysosomal mechanism represent a meaningful step in neurodegenerative drug development.
Detailed Summary
Neurodegeneration is one of the greatest threats to healthy aging, and two of its most common forms — Alzheimer's and Parkinson's disease — both involve the toxic buildup of misfolded proteins inside aging brain cells. A Cambridge, Massachusetts biotech called Lysoway Therapeutics believes the solution may lie in reactivating the brain's own cleanup machinery, and its lead drug LW-1017 has now shown promising results in aged mouse models of both conditions.
LW-1017 is an oral small-molecule drug that targets TRPML1, a calcium channel sitting on the surface of lysosomes — the organelles responsible for breaking down and recycling cellular waste. Activating TRPML1 triggers a signaling cascade that switches on genes involved in autophagy and lysosome production, effectively turning up the cell's self-cleaning capacity. When TRPML1 was absent in cell experiments, the drug's effects disappeared, confirming target specificity.
In aged Parkinson's mouse models, LW-1017 reduced abnormal alpha-synuclein aggregates, preserved dopamine-producing neurons, and improved motor performance on a ladder-rung walking test. In aged Alzheimer's mouse models, it lowered amyloid and tau pathology, reduced brain inflammation, and improved memory in a water maze task. These benefits appeared at oral doses as low as 3 mg/kg, with robust brain exposure confirmed across doses tested.
A head-to-head comparison at 30 mg/kg found that a less brain-penetrant but equally potent comparator drug failed to match LW-1017's benefits, highlighting that brain penetrance is critical for both efficacy and safety — since TRPML1 is expressed throughout the body, high brain specificity reduces peripheral off-target effects.
Important caveats apply. All data come from mice, and neurodegeneration research has a long history of mouse results failing in humans. The company provided no raw effect-size numbers in the press release. LW-1017 is currently in Phase I single and multiple ascending dose trials in healthy volunteers — patient data are still years away.
Key Findings
- LW-1017 reduced alpha-synuclein clumps and preserved dopamine neurons in aged Parkinson's mouse models.
- In aged Alzheimer's mice, the drug lowered amyloid and tau pathology and improved memory scores.
- Oral dosing achieved strong brain penetration at doses as low as 3 mg/kg with sustained autophagy markers.
- A less brain-penetrant comparator drug failed to match LW-1017's benefits at 30 mg/kg, underscoring penetration's role.
- TRPML1 activation restores lysosomal cleanup function — a mechanism potentially relevant across multiple neurodegenerative diseases.
Methodology
This is a news report summarizing a peer-reviewed preclinical study published in Scientific Reports, a Nature Portfolio open-access journal. Evidence is entirely from cell experiments and aged mouse models; no human clinical efficacy data exist yet. The source article is from Longevity.Technology, a credible longevity-focused outlet, but the findings originate from the company's own research team.
Study Limitations
All efficacy data come from mouse models, and neurodegeneration drugs have a notoriously poor translational record from rodents to humans. No quantitative effect sizes were reported in the press release; readers should consult the open-access Scientific Reports paper for full data. Phase I trials are testing safety in healthy volunteers only — therapeutic benefit in patients has not been demonstrated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: